跳至主要内容
临床试验/NCT06181422
NCT06181422招募中2 期

Comparative Study to Evaluate the Safety and Possible Efficacy of Metformin Versus Lactoferrin in ICU Patients With

Tanta University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
60
试验地点
1
主要终点
The primary endpoint is mortality rate

研究概览

简要总结

Sepsis is a life-threatening organ dysfunction triggered by an unregulated response of a host to infection. Sepsis is a reason for substantial mortality and morbidity among intensive care unit (ICU) patients. 1 Therefore, the aim of our study is to compare the safety and efficacy of metformin and lactoferrin in ICU patients with sepsis.

详细描述

Sepsis is a life-threatening organ dysfunction triggered by an unregulated response of a host to infection. Sepsis is a reason for substantial mortality and morbidity among intensive care unit (ICU) patients. 1 The pathophysiology of sepsis has changed spectacularly over the last several decades. Significant comprehension into the components of the inflammatory response has been achieved. Inflammation contributes to endothelial injury and initiates coagulation pathways.2 The inflammatory reaction is mediated by the release of cytokines (tumor necrosis factor-alpha, interleukins, and prostaglandins) from neutrophils and macrophages. The cytokines trigger the extrinsic coagulation cascade and inhibit fibrinolysis. These overlapping processes end with organ dysfunction.3 The Sequential Organ Failure Assessment or SOFA score was developed to assess the acute morbidity of critical illness at a population level and has been extensively validated as a tool for this purpose across a range of healthcare settings and environments.4 Metformin is oral anti-diabetic agent that has positive effects such as antioxidant and anti-inflammatory properties which are considered potentially beneficial properties for management of septic patients. Previous studies showed that preadmission metformin use may reduce mortality in adult patients with sepsis and diabetes mellitus. Therefore, our study aims to test the potential efficacy of metformin in all subsets of patient with sepsis.5,6 Lactoferrin is a cationic glycoprotein and associated with many activities including the relevant anti-inflammatory one, especially associated to the downregulation of pro-inflammatory cytokines besides its anti-microbial and immunomodulatory effect.7 A previous study suggested that lactoferrin supplementation to enteral feeds with or without probiotics decreases late-onset sepsis in preterm infants without adverse effects and this encourage us to test its role in adult patients with sepsis.8 Therefore, the aim of our study is to compare the safety and efficacy of metformin and lactoferrin in ICU patients with sepsis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion Criteria:
  • Age more than 18 years old.
  • A diagnosis of sepsis according to the latest Sepsis definition.11
  • Estimated GFR >45 ml/minute.

排除标准

  • Exclusion Criteria:
  • Pregnancy and breast feeding.
  • End stage hepatic disease.
  • End stage renal disease -

研究组 & 干预措施

Group 2 :Lactoferrin

Active Comparator

Group 2 :(Lactoferrin, n=30) who will receive lactoferrin 100 mg three times daily

干预措施: Lactoferrin (Drug)

Group1: Metformin

Active Comparator

Group1: (Metformin, n=30) who will receive metformin 500 mg three times daily.

干预措施: Metformin (Drug)

结局指标

主要结局

The primary endpoint is mortality rate

时间窗: 28 days

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alaa Mohamed Hemida

Dr

Tanta University

研究点 (1)

Loading locations...

相似试验

Metformin and Lactoferrin in Sepsis in Icu | 临床试验